Open AccessCatheter-based radiofrequency renal sympathetic denervation for resistant hypertension; initial Egyptian experience
Author(s) -
Hazem Khamis,
Ahmed Abdelaziz,
Ahmed Ramzy
Publication year - 2014
Publication title -
the egyptian heart journal /the egyptian heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.212
H-Index - 9
eISSN - 2090-911X
pISSN - 1110-2608
DOI - 10.1016/j.ehj.2013.08.006
Subject(s) - medicine , renal sympathetic denervation , blood pressure , denervation , percutaneous , catheter , adverse effect , cardiology , essential hypertension , renal artery , renal function , radiofrequency ablation , plasma renin activity , catheter ablation , clinical endpoint , resistant hypertension , surgery , anesthesia , ablation , kidney , renin–angiotensin system , clinical trial
AbstractObjectivesTo evaluate the feasibility, efficacy, and safety of catheter-based radiofrequency renal sympathetic denervation for treatment of resistant hypertension.BackgroundIn a subpopulation of patients with essential hypertension, therapeutic targets are not met, despite the use of multiple types of medication. In this paper we describe our first experience with a novel percutaneous treatment modality using renal artery radiofrequency (RF) ablation.MethodsThirty patients with essential hypertension unresponsive to at least three types of antihypertensive medical therapy (baseline office systolic blood pressure ⩾160mmHg) were selected between March and September 2012 and received percutaneous RF ablation. Patients were followed up for 6months after treatment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6months. Another thirty patients were taken as control.ResultsA reduction of mean office blood pressure was seen from 170/102±9/5mmHg at baseline to 151/91±8/6mmHg at 6months follow-up (p=0.001). Also, we noted a significant decrease in plasma renin activity (3.66±0.64 versus 3.37±0.47ng/mL/h; p=0.003). No periprocedural complications, adverse events or change in renal function were noted during follow-up.ConclusionCatheter-based renal denervation seems an attractive minimally invasive treatment option in patients with resistant hypertension, with a low risk of serious adverse events